A detailed history of Twin Capital Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Twin Capital Management Inc holds 82,849 shares of BMY stock, worth $4.79 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
82,849
Previous 60,769 36.33%
Holding current value
$4.79 Million
Previous $2.52 Million 69.92%
% of portfolio
0.5%
Previous 0.3%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $875,692 - $1.14 Million
22,080 Added 36.33%
82,849 $4.29 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $728,001 - $958,430
-18,087 Reduced 22.94%
60,769 $2.52 Million
Q1 2024

May 13, 2024

SELL
$47.98 - $54.4 $206,601 - $234,246
-4,306 Reduced 5.18%
78,856 $4.28 Million
Q4 2023

Jan 31, 2024

BUY
$48.48 - $57.85 $476,606 - $568,723
9,831 Added 13.41%
83,162 $4.27 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $892,142 - $997,554
-15,411 Reduced 17.37%
73,331 $4.26 Million
Q2 2023

Aug 07, 2023

BUY
$63.71 - $70.74 $301,220 - $334,458
4,728 Added 5.63%
88,742 $5.68 Million
Q1 2023

May 08, 2023

SELL
$65.71 - $74.53 $682,858 - $774,515
-10,392 Reduced 11.01%
84,014 $5.82 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $186,950 - $221,375
-2,730 Reduced 2.81%
94,406 $6.79 Million
Q3 2022

Oct 21, 2022

SELL
$0.13 - $76.84 $160 - $94,590
-1,231 Reduced 1.25%
97,136 $6.91 Million
Q2 2022

Aug 02, 2022

SELL
$72.62 - $79.98 $96,003 - $105,733
-1,322 Reduced 1.33%
98,367 $7.57 Million
Q1 2022

May 06, 2022

BUY
$61.48 - $73.72 $15,984 - $19,167
260 Added 0.26%
99,689 $7.28 Million
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $135,683 - $158,175
-2,530 Reduced 2.48%
99,429 $6.2 Million
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $423,657 - $496,259
-7,160 Reduced 6.56%
101,959 $6.03 Million
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $131,249 - $142,930
2,120 Added 1.98%
109,119 $7.29 Million
Q1 2021

May 06, 2021

SELL
$59.34 - $66.74 $129,361 - $145,493
-2,180 Reduced 2.0%
106,999 $6.76 Million
Q4 2020

Feb 11, 2021

SELL
$57.74 - $65.43 $269,761 - $305,688
-4,672 Reduced 4.1%
109,179 $6.77 Million
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $148,226 - $164,254
-2,581 Reduced 2.22%
113,851 $6.86 Million
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $2,741 - $3,204
-50 Reduced 0.04%
116,432 $6.85 Million
Q1 2020

Apr 29, 2020

SELL
$46.4 - $67.43 $32,944 - $47,875
-710 Reduced 0.61%
116,482 $6.49 Million
Q4 2019

Jan 29, 2020

SELL
$49.21 - $64.19 $1.41 Million - $1.84 Million
-28,680 Reduced 19.66%
117,192 $7.52 Million
Q3 2019

Oct 28, 2019

SELL
$42.77 - $50.71 $107,780 - $127,789
-2,520 Reduced 1.7%
145,872 $7.4 Million
Q2 2019

Aug 01, 2019

SELL
$44.62 - $49.34 $2.59 Million - $2.86 Million
-58,058 Reduced 28.12%
148,392 $6.73 Million
Q1 2019

May 03, 2019

BUY
$45.12 - $53.8 $229,660 - $273,842
5,090 Added 2.53%
206,450 $9.85 Million
Q4 2018

Feb 04, 2019

SELL
$48.76 - $63.23 $110,197 - $142,899
-2,260 Reduced 1.11%
201,360 $10.5 Million
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $360,942 - $407,115
6,540 Added 3.32%
203,620 $12.6 Million
Q2 2018

Aug 13, 2018

BUY
$50.53 - $62.98 $382,006 - $476,128
7,560 Added 3.99%
197,080 $10.9 Million
Q1 2018

May 01, 2018

SELL
$59.92 - $68.98 $476,963 - $549,080
-7,960 Reduced 4.03%
189,520 $12 Million
Q4 2017

Jan 29, 2018

SELL
$59.94 - $65.35 $651,367 - $710,158
-10,867 Reduced 5.22%
197,480 $12.1 Million
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $1.05 Million - $1.21 Million
18,976 Added 10.02%
208,347 $13.3 Million
Q2 2017

Aug 07, 2017

BUY
N/A
189,371
189,371 $10.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Twin Capital Management Inc Portfolio

Follow Twin Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Twin Capital Management Inc with notifications on news.